It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Eli Lilly and Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is now ...
That equates to 45 to 50 pounds of weight loss, on average, over a year, Lilly said. Patients on the drug also saw reductions ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro ... selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against ...